Stringer 1995

Methods	Retrospective cohort study
Participants	N of patients original cohort: 26; N of patients described study group: 26; N of patients study group of interest: 26; N of patients with liver function tests: 26 Tumour: Hepatoblastoma; Time period diagnosis/treatment: 1981‐1993; Age at diagnosis: median 1.3 (0.0 ‐ 12.0)a; Age at follow‐up: nm; F/M%: 39/61a; BMI: nm N of patients hepatitis virus infection: nm N of patients acute liver disease: nm Follow‐up duration: median 5.3 (0.1‐12.2) yr; Completion of follow‐up: 100%
Interventions	N of patients chemotherapy: 24/26 (92.3%); Chemotherapy type: cisplatin, doxorubicin, carboplatin and etoposide; Chemotherapy dose: 3‐weekly cisplatin (80‐100 mg/m2) and doxorubicin (50‐60 mg/m2) N of patients radiotherapy involving the liver: 2/26 (7.7%); Radiotherapy field: nm; Radiotherapy dose: nm N of patients hepatectomy: 26/26 (100%) N of patients BMT: nm N of patients blood transfusion: nm
Outcomes	Method of detection of hepatic late adverse effects: Biochemical liver function tests (frequency of testing nm) Definition of hepatic late adverse effects: nm N of patients hepatic late adverse effects at end of follow‐up: 0/26 (0.0%) Risk factors: not evaluated
Notes	a Data of 41 patients with hepatoblastoma
Risk of bias
Bias	Authors' judgement	Support for judgement
Representative study group	Low risk	Described study group consisted of more than 90% of the original cohort
Complete follow‐up assessment	Low risk	Outcome was assessed for more than 90% of the study group of interest
Blinded outcome assessor	Unclear risk	Unclear if outcome assessors were blinded to the investigated determinant
Well defined study group	High risk	Number of patients with hepatitis virus infection was not mentioned
Well defined follow‐up	Low risk	Length of follow‐up was mentioned
Well defined outcome	High risk	Outcome definition was not objective and precise